Terry Dagnon - 17 Apr 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: Chief Operations Officer
Issuer ticker: OTLK
Reported as of: 17 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Apr 2023, 17:41:39 UTC
Prior SEC filing: 23 Jun 2022
Next SEC filing: 21 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Lawrence Kenyon, Attorney-in-Fact

Key filing fact

Terry Dagnon filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 19 Apr 2023.

Key facts

This page summarizes Terry Dagnon's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Apr 2023, 17:41.

Change

Previous filing in this sequence was filed on 23 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +192,143
Change %
Price: $0.000000
Shares after: 192,143
Date: 17 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 192,143
Exercise price: $1.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option shall vest on April 17, 2024, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.